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A B S T R A C T
Introduction: Previous studies have reported an acquiredBRAF V600E mutation as a potential resistance me-
chanism to osimertinib treatment in advanced NSCLC patients with an activating mutation in EGFR. However,
the therapeutic effect of combining dabrafenib and trametinib with osimertinib remains unclear. Here we report
treatment efficacy in two cases with acquired BRAF V600E mutations.
Methods: Two patients with anEGFR exon 19 deletion and a T790M mutation, both treated with osimertinib,
acquired a BRAF V600E mutation at disease progression. Following the recommendation of the molecular tumor
board, a concurrent combination of dabrafenib and trametinib plus osimertinib was administered.
Results: Because of toxicity, one patient ultimately received a reduced dose of dabrafenib and trametinib
combined with a normal dose of osimertinib. Clinical response in this patient lasted for 13.4 months. Re-biopsy
upon tumor progression revealed loss ofBRAF V600E and emergence of EGFR C797S. The other patient, treated
with full doses of the combined therapy, had progression with metastases in lung and brain one month after
starting therapy.
Conclusion: BRAF V600E may be a resistance mechanism induced by osimertinib in EGFR-mutated advanced
NSCLC. Combined treatment using dabrafenib/trametinib concurrently with osimertinib needs to be explored for
osimertinib-induced BRAF V600E mutation.
1. Introduction
Osimertinib was approved by the Food and Drug Administration in
2018 for the treatment of epidermal growth factor receptor (EGFR)-
mutant non-small-cell lung cancer (NSCLC) patients. At first, osi-
mertinib was used only for patients with acquired T790M mutations
after 1st and/or 2nd generation EGFR tyrosine kinase inhibitor (TKI)
treatment, but it more recently began to be used in first line treatment
of EGFR-mutant patients [1]. Despite good initial responses, patients
developed resistance to second-line osimertinib treatment, with a
median time to progression of 10.1 months [2]. Several mechanisms to
explain this resistance have been identified, including an acquired v-raf
murine sarcoma viral oncogene homolog B1 (BRAF) V600E mutation
[2]. Treatment options for patients with acquired BRAF V600E have not
been established and are still in an early phase of development.
Here we report treatment outcomes of dual inhibition of EGFR and
BRAF for two NSCLC patients who developed resistance to osimertinib
in second-line treatment, both with a BRAF V600E mutation as a po-
tential acquired mechanism of resistance to osimertinib. We also pro-
vide an overview of the treatment outcomes for all reported cases with
acquired BRAF V600E mutations.
2. Material and methods
Retrospective analysis of NSCLC patients with actionable EGFR
mutations treated with osimertinib between January 1, 2015 and
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March 1, 2020 revealed a BRAF V600E mutation in 2 of 80 NSCLC
patients. Re-analysis of the pre- and post-osimertinib samples was
performed for BRAF V600E using the highly sensitive droplet digital
polymerase chain reaction (ddPCR) assay (dHsaMDV2010027 [Bio-
Rad, Hercules, CA]) following standard procedures, as described pre-
viously [3]. The two patients were anonymized for the investigators.
The study protocol complies with the Research Code of the University
Medical Center Groningen (https://www.rug.nl/umcg/research/
documents/research-code-info-umcg-nl.pdf) and national ethical and
professional guidelines (“Code of conduct; Dutch federation of biome-
dical scientific societies”, htttp://www.federa.org).
3. Cases
Patient 1 was a 56-year-old never smoking Caucasian female diag-
nosed with a stage IV adenocarcinoma of the lung. An EGFR exon 19
deletion (E19del) (p.L747_A750delinsP) was identified by next gen-
eration sequencing (NGS) using an amplicon-based Ion Torrent plat-
form on plasma DNA. The patient received afatinib as first-line treat-
ment. After 11 months, she had progressive disease with an EGFR
T790M in addition to the previously observed EGFR E19del. Therefore,
osimertinib was started as a second-line treatment. After about 8.5
months, the patient presented with progressive disease in lung and
brain. Re-biopsy of the lung lesion and NGS showed loss of the EGFR
T790M and gain of a BRAF V600E in addition to the EGFR E19del. To
establish whether the BRAF V600E was pre-existing or acquired, we
performed ddPCR on the earlier biopsy taken from axillar lymph node.
No BRAF V600E mutant droplets were detected in the pre-osimertinib
sample, while there were 6,740 wild-type BRAF droplets, equaling a
limit of detection of 0.04 %. As both biopsies originated from the same
site, this indicates that the mutation developed during osimertinib
treatment. After clinical discussion, the patient started treatment with
dabrafenib and trametinib plus osimertinib concurrently. The patient
responded clinically within 2 weeks, although brain metastases pro-
gressed at magnetic resonance imaging (MRI) after 6 weeks. Treatment
had to be stopped because of a pneumonitis (Fig. 1A). The clinical
condition of the patient was then not good enough to start new treat-
ment, and she died 5 months later.
Patient 2 was a 66-year-old never smoking Caucasian male diag-
nosed with a stage IV adenocarcinoma of the lung. Diagnostic tests
revealed an EGFR E19del (p.E746_A750del) in the baseline tumor
biopsy. The patient received gefitinib treatment for a total period of
11.2 months. At disease progression, an EGFR T790M mutation was
detected in addition to the previously detected EGFR E19del, and osi-
mertinib was administered. A partial tumor response was observed that
was sustained for 20 months. Analysis of a biopsy taken at progression
indicated presence of a BRAF V600E in addition to the previously ob-
served EGFR E19del and T790M. Re-analysis by ddPCR of the pre- and
post-osimertinib biopsies, both taken from the subcarinal lymph node,
confirmed BRAF V600E in the post-osimertinib sample and no detect-
able BRAF-V600E mutation in the pre-osimertinib sample. The limit of
detection was 0.06 %, with a total 5,212 BRAF wild-type droplets in the
pre-osimertinib sample. Based on the observed mutations, the patient
was treated with a combination of dabrafenib and trametinib plus
osimertinib. The patient showed a partial tumor response for all tumor
sites, but required dose reduction because of repeated grade 2 pyrexia,
a common toxicity criteria (V 4.0), grade 2 nausea and grade 2 vo-
miting. The treatment was reduced to 50mg BID (twice per day) dab-
rafenib, 0.5 mg QD (once per day) trametinib and 80mg QD osi-
mertinib. Tumor mass showed a remarkable reduction after 3 months
according to the positron emission tomography–computed tomography
(PET-CT) image (Fig. 1B). After 13.4 months, the patient had pro-
gressive disease with disappearance of the BRAF V600E and an ac-
quired EGFR C797S that coexisted with the previously observed EGFR
E19del at similar variant allele frequencies (VAF) (77 % and 83 %,
respectively), while the T790M mutation was observed only at a very
low frequency (VAF of 2%). The absence of the BRAF V600E mutation
was confirmed using ddPCR, with 36,119 wild-type droplets and no
mutant droplets, reaching a limit of detection of 0.008 %. Based on
these results, and after evaluation by our molecular tumor board, ge-
fitinib treatment was proposed and started. Three weeks after start of
this treatment, the clinical condition of the patient worsened rapidly as
a result of pneumonitis without tumor progression, and the patient died
a few days later.
4. Discussion
BRAF V600E is a known oncogenic driver occurring in approxi-
mately 2 % of all NSCLC [4]. Clinical studies have shown good anti-
tumor effects of the BRAF inhibitor dabrafenib in combination with the
MEK inhibitor trametinib in initial BRAF V600E-mutated NSCLC pa-
tients [5]. However, the effectiveness of dabrafenib and trametinib plus
osimertinib as a treatment strategy for NSCLC patients where BRAF
V600E is a possible resistance mechanism to EGFR TKI treatment is
largely unknown. In our two cases, the BRAF V600E mutation is most
likely an acquired osimertinib-resistance mutation, as we could not
detect the BRAF V600E in pre-treatment biopsies using ddPCR. One of
the two patients included in our study had brain metastases, and the
main clinical deterioration under treatment came from progression of
brain metastases. This patient did not respond to the treatment, pos-
sibly due to limited drug penetration across the blood-brain barrier [6]
or to a novel resistance mechanism in the brain metastasis. The other
patient responded to the treatment for 14 months until loss of the BRAF
V600E mutation and induction of a new resistant mutation (EGFR
C797). In both patients, a pneumonitis developed on TKI after exposure
to the combined treatment. We do not know whether this is caused by
the treatment.
So far, treatment outcome has been reported for five cases (Table 1).
One patient demonstrated a reduction of tumor size after 2 weeks of
dabrafenib/trametinib and a slight increase 4 weeks thereafter [7]. A
second patient presented with clinical progression after 4 weeks of
dabrafenib and trametinib treatment. After switching treatment to a
combination of both osimertinib and dabrafenib, an impressive meta-
bolic response was observed by 18F-2-fluoro-2-deoxy-D-glucose (FDG)
PET/CT (−33 %) within 2 weeks [7]. The third patient was treated
with dabrafenib and trametinib alternated with osimertinib because of
hepatic progression in which a BRAF V600E was detected [8]. This
patient responded to treatment for 6 months. The last two cases (one
with an EGFR E19del and one with a L858R) were treated with a
combination of dabrafenib, trametinib and osimertinib concurrently,
after acquiring a BRAF V600E mutation upon treatment with osi-
mertinib, which had been administrated based on an acquired T790M
[9,10]. Both patients demonstrated tumor shrinkage during reported
treatment times of 2 and 7 months, respectively. Treatment was on-
going at the time of the case reports, so the PFS time was not yet known.
Despite the limited number of patients treated thus far, promising re-
sults have been obtained with the combined treatment.
In conclusion, our data indicate that the TKI-induced BRAF V600E
mutation is an acquired resistance mechanism to osimertinib. Of the
five patients receiving combined dabrafenib, trametinib and osi-
mertinib, the four patients without brain metastasis showed a clinical
response, while the fifth patient with brain metastasis did not respond.
Combined treatment with dabrafenib/trametinib and osimertinib thus
seems to be effective, especially in patients without brain metastasis. To
define the most optimal treatment strategy for patients with EGFR-ac-
tivating mutations who develop BRAF V600E mutations after initial
response, further studies with similar treatment regimens and data on
PFS and OS are required.
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